Aarhus University Seal / Aarhus Universitets segl

Claus Oxvig

Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Cheryl A. Conover, Mayo Clinic
  • ,
  • Laurie K. Bale, Mayo Clinic
  • ,
  • Claus Oxvig

The metalloproteinase, pregnancy-associated plasma protein-A (PAPP-A), has been implicated in the development of cardiovascular disease in humans and mouse models. In the latter, genetic deletion or overexpression of PAPP-A confirmed a major role for PAPP-A in atherosclerosis. In this study, we tested the hypothesis that targeting PAPP-A proteolytic activity by an inhibitory monoclonal antibody (mAb-PA) reduces atherosclerotic plaque progression. Apolipoprotein E knock-out mice on high-fat diet were treated with mAb-PA or isotype control. Control mice had a 10-fold increase in aortic plaque after 10 weeks. Aortic plaque burden was reduced by ∼70 % in mice treated with mAb-PA (P = 0.0002). Treatment was efficacious even in the face of elevated cholesterol and triglycerides. This study demonstrates proof-of-principle and provides feasibility for a novel therapeutic strategy to inhibit atherosclerotic plaque burden by selective targeting of PAPP-A.

Original languageEnglish
JournalJournal of Cardiovascular Translational Research
Pages (from-to)77-79
Number of pages3
Publication statusPublished - 1 Feb 2016

    Research areas

  • Atherosclerosis, Insulin-like growth factor, Monoclonal antibody, Pregnancy-associated plasma protein-A

See relations at Aarhus University Citationformats

ID: 104051101